A5072720767- Antibiotics Pharmacokinetics and Efficacy
- Pharmaceutical studies and practices
- Drug Solubulity and Delivery Systems
- Advanced Drug Delivery Systems
- Treatment of Major Depression
- Tryptophan and brain disorders
- Protein purification and stability
- Neonatal Health and Biochemistry
- Neonatal Respiratory Health Research
- Anesthesia and Sedative Agents
- Retinopathy of Prematurity Studies
- Salivary Gland Disorders and Functions
- Atrial Fibrillation Management and Outcomes
- Wound Healing and Treatments
- Polymer Surface Interaction Studies
- Diabetes Management and Research
- Analytical Chemistry and Chromatography
- Oral microbiology and periodontitis research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Venous Thromboembolism Diagnosis and Management
- Pancreatic function and diabetes
- Drug-Induced Hepatotoxicity and Protection
- Diabetes and associated disorders
- Cancer Treatment and Pharmacology
- Proteins in Food Systems
University of Otago
2014-2024
Pharmac
2015-2017
University of Kansas
1998
The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities brain network depression anxiety disorders, we hypothesized that might also be active other refractory disorders. We evaluated the efficacy safety of 12 patients with generalized and/or social who were not currently depressed, using an ascending single dose study design (0.25, 0.5, 1 mg/kg...
Objective: In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months weekly ketamine in 20 patients with treatment-refractory DSM IV generalised disorder (GAD) and/or social (SAD), subsequent assessment remission post-treatment. Methods: This was an uncontrolled open-label study who had been responders ascending dose study. The undertaken a university clinic. Patients received one or two doses 1 mg/kg injected subcutaneously...
Background: We previously reported that ketamine has anxiolytic effects in patients with treatment-resistant generalized anxiety and social disorders. Aims: The purpose of this study was to replicate our earlier report about ketamine‘s activity, using a more robust design. Methods: This double-blind, psychoactive-controlled ascending dose 12 disorders who were not currently depressed. Ascending doses (0.25, 0.5, 1 mg/kg) administered at weekly intervals, midazolam 0.01 mg/kg, the control,...
Background: The N-methyl-D-aspartate antagonist ketamine has rapid onset antidepressant activity in treatment-resistant depression (TRD). Aims: To evaluate mood rating, safety and tolerability data from patients with TRD treated the psychoactive control fentanyl, as part of a larger study to explore EEG biomarkers associated response. Methods: We evaluated efficacy intramuscular racemic 25 TRD, using double-blind active-controlled randomized crossover design. Ketamine doses were 0.5 1 mg/kg,...
We compared the test characteristics of interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12(p-70), tumor necrosis factor-α (TNF-α), procalcitonin (PCT), C-reactive protein (CRP), and full blood count (FBC) in diagnosis neonatal sepsis. This prospective cohort study Neonatal Intensive Care Unit Dunedin hospital patients between July 1, 2002 February 28, 2007 included 117 neonates commenced on antibiotics for 164 episodes suspected Blood cultures, FBC, CRP, IL-1β, TNF-α, PCT were obtained at time...
Abstract Parenteral ketamine has fast‐onset antidepressant and antianxiety effects; however, it causes dissociation, hypertension, tachycardia shortly after dosing. Ketamine's effects may be due to active metabolites rather than itself. We hypothesized that oral controlled‐release tablets would improve safety tolerability compared with injected by reducing peak exposures dosing injection. In this randomized, placebo‐controlled ascending‐dose study, doses of 60, 120, or 240 mg matching...
Recently, New Zealand has taken a system wide approach providing the biggest reform to community pharmacy for 70 years with aim of more clinically orientated patient centred services through new funding model. The this study was understand types offered in pharmacies since introduction model, what barriers are these services. A survey all were undertaken between August, 2014 and February, 2015. Basic descriptive statistics completed group comparisons made using chi squared test significance...
Ketamine's defining side effects are dissociation and increased blood pressure/heart rate. An oral formulation with delayed absorption could minimize these effects. We recently reported safety tolerability data for an extended release ketamine tablet in healthy volunteers.To assess safety, tolerability, efficacy, pharmacokinetics of patients treatment-resistant depression/anxiety. This was a multiple dose open-label flexible uncontrolled study seven depression/anxiety, who had all previously...
Abstract The development of optimized dosing regimens plays a crucial role in oncology drug development. This study focused on the population pharmacokinetic modelling and simulation docetaxel, comparing exposure oral docetaxel plus encequidar (oDox + E) with standard care intravenous (IV) regimen. aim was to evaluate feasibility oDox E as potential alternative IV docetaxel. article demonstrates an approach which aligns FDA’s Project Optimus aims improve through model informed (MIDD). key...
SUMMARY The aim of the present study was to perform an in vivo estimation Michaelis‐Menten constants major metabolic pathways paracetamol (APAP). A two‐occasion, single‐dose cross‐over trial performed using 60 and 90 mg/kg doses APAP healthy patients undergoing third molar dental extraction. Plasma samples were collected over 24 h urine for 8 after dosing. Twenty enrolled complete data plasma available both 13 volunteers who included analysis; seven men, median age (range) 22 years (19–31)...